{"schema":"hottub-news/story/v1","story":"st_h74imxfqrr23pwsua5wq","title":"네오이뮨텍 ‘NT-I7’ 美 파트너, 日 타나베파마 항체 도입","title_en":"Neoimmunetech's 'NT-I7' US partner, Tanabe Pharma antibody introduction","outlets":1,"brief":null,"page":"https://hottub.news/stories/neoimmunetechs-nt-i7-us-partner-tanabe-pharma-antibody-introduction-h74imxfqrr","count":1,"items":[{"id":"n_h74imxfqrr23pwsua5wq","seq":799644,"kind":"article","title":"네오이뮨텍 ‘NT-I7’ 美 파트너, 日 타나베파마 항체 도입","title_en":"Neoimmunetech's 'NT-I7' US partner, Tanabe Pharma antibody introduction","url":"https://www.etoday.co.kr/news/view/2630702","summary":"네오이뮨텍의 장기지속형 인터루킨-7 후보물질 ‘NT-I7’의 임상 개발에 속도가 붙을 전망이다. 기술수출 파트너인 미국 톨러런...","published":"2026-09-30T00:40:00Z","seen":"2026-09-30T01:33:17Z","lang":"ko","country":"KR","source":{"id":"kite-etoday-co-kr-278ce9","name":"etoday.co.kr","domain":"rss.etoday.co.kr"},"via":"kite-etoday-co-kr-278ce9","topics":["일반"],"authors":["이상민","author"],"entities":[{"id":"Q131188121","name":"NeoImmuneTech","type":"org"},{"id":"Q6883161","name":"Tanabe Pharma","type":"org"}],"story":"st_h74imxfqrr23pwsua5wq","category":"science-technology","category_p":0.44999998807907104,"sentiment":"neutral","tone":0.2800000011920929,"political":0.15000000596046448}]}